Pages 405-420 (doi:10.405) Clinical trials with thiazolidinediones in subjects with Type 2 diabetes - is pioglitazone any different from rosiglitazone?Doggrell PhD DScRMIT University, Pharmaceutical Sciences, School of Medical Sciences, PO Box 71, Victoria 3083, Australia +61 3 99257161; +61 3 99257063; The thiazolidinediones, rosiglitazone and pioglitazone are used in the treatment of Type 2 diabetes (T2DM).Have been shown to decrease glycated haemoglobin levels, fasting plasma glucose, insulin, and free fatty acids levels in subjects with T2DM.These agents have markedly different effects on lipids.Increases total, low- and high-density lipoprotein (LDL and HDL) cholesterol, and triglycerides, whereas pioglitazone has no effect on total or LDL cholesterol, increases HDL cholesterol and decreases triglycerides.Rosiglitazone and pioglitazone decrease inflammatory markers.Both rosiglitazone and pioglitazone may cause a small decrease in blood pressure, improve endothelial function and reduce restenosis.Is also reduced by both rosiglitazone and pioglitazone.The improvements in surrogate end points, there is little clear evidence that either rosiglitazone or pioglitazone cause major improvements in cardiovascular oues.Rosiglitazone has no effect or may even increase cardiovascular oues, whereas, in high-risk subjects, pioglitazone has a marginal ability to decrease cardiovascular oues.Thiazolidinediones are shown to improve cardiovascular or other oues (e.Read more A fatal case of recurrent amiodarone-induced thyrotoxicosis after percutaneous tracheotomy: a case report
Get more Triamcinolone: nocardia infection following subtenon administration: case report
